Hyderabad-based Bharat Biotech has been given permission to begin the second and third phase clinical trial to assess the safety and immunity of Covaxin on children aged two to 18 years. The trial will be conducted on 525 volunteers at various centers in the country, including AIIMS in Delhi and Patna and the Meditrina Institute of Medical Sciences in Nagpur. Bharat Biotech has developed Covaxin in collaboration with the Indian Council of Medical Research (ICMR). The company is also producing and marketing it. In India, Covaxin is being used along with Serum Institute of India’s Covishield in vaccination campaigns.
*Please create a profile first to EARN & REDEEM points
Bharat Biotech to begin trial of Covaxin vaccine for age group 2 to 18
We are building a board of industry expert to help us verify important news stories. If you would like to empanel yourself, please click here.